Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancers that are difficult to treat. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors. The company is building a pipeline of next-generation DDR programs, including through …

University of Cambridge technology spin-out Zetta Genomics is a leader in large-scale genomic data management for precision medicine. It is employing big data technology and best practice security to leverage genomic data benefits while preserving data privacy. The company’s flagship offering, the XetaBase platform, is a genomic data management technology that powers the discovery and …

Founded in 2006, 23andMe is the leading consumer genetics and research company. Its test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The company’s services include ancestry, health and traits genetic insights …